Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (12): 1284-1287.DOI: 10.3969/j.issn.1673-8640.2020.12.019
Previous Articles Next Articles
Received:2019-10-28
Online:2020-12-30
Published:2020-12-31
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2020.12.019
| 组别 | PCT/（μg/L） | CRP/（mg/L） | WBC计数/ （×109/L） | NEUT#/ （×109/L） | NEUT%/% | PCT×NEUT% |
|---|---|---|---|---|---|---|
| G+球菌败 血症组 | 0.75（0.18~5.78） | 97.85（49.86~194.02） | 12.65（8.22~20.64） | 9.74（5.39~17.22） | 81.11（61.43~89.50） | 67.3（12.6~425.6） |
| G-杆菌败 血症组 | 35.67（7.88~100.00） | 177.84（76.16~200.00） | 11.89（8.15~21.16） | 10.15（6.44~18.73） | 88.54（82.02~93.46） | 3 17.0 （588.6~8 957.0） |
| Z值 | -4.909 | -1.898 | -0.064 | -0.611 | -2.886 | 173.00 |
| P值 | 0.000 | 0.058 | 0.949 | 0.541 | 0.004 | 0.000 |
| 组别 | PCT/（μg/L） | CRP/（mg/L） | WBC计数/ （×109/L） | NEUT#/ （×109/L） | NEUT%/% | PCT×NEUT% |
|---|---|---|---|---|---|---|
| G+球菌败 血症组 | 0.75（0.18~5.78） | 97.85（49.86~194.02） | 12.65（8.22~20.64） | 9.74（5.39~17.22） | 81.11（61.43~89.50） | 67.3（12.6~425.6） |
| G-杆菌败 血症组 | 35.67（7.88~100.00） | 177.84（76.16~200.00） | 11.89（8.15~21.16） | 10.15（6.44~18.73） | 88.54（82.02~93.46） | 3 17.0 （588.6~8 957.0） |
| Z值 | -4.909 | -1.898 | -0.064 | -0.611 | -2.886 | 173.00 |
| P值 | 0.000 | 0.058 | 0.949 | 0.541 | 0.004 | 0.000 |
| 炎性指标 | 最佳临界值值 | 曲线下面积 | 95%可信区间 | P值 | 敏感性/ % | 特异性/ % | 准确度/ % | 阴性预测值/% | 阳性预测值/% |
|---|---|---|---|---|---|---|---|---|---|
| PCT/（μg/L） | 2.295 | 0.852 | 0.758~0.946 | 0.000 | 87.9 | 72.1 | 83.6 | 71.5 | 88.1 |
| WBC计数/（×109/L） | 26.47 | 0.505 | 0.365~0.644 | 0.949 | 17.0 | 100.0 | 41.3 | 33.3 | 100.0 |
| NEUT#/（×109/L） | 19.435 | 0.545 | 0.404~0.686 | 0.541 | 24.5 | 95.5 | 45.3 | 34.4 | 92.9 |
| NEUT%/% | 85.55 | 0.713 | 0.583~0.842 | 0.004 | 67.9 | 68.2 | 68.0 | 46.9 | 83.7 |
| CRP/（mg/L） | 162.5 | 0.638 | 0.499~0.777 | 0.061 | 60.4 | 72.7 | 64.0 | 43.2 | 84.2 |
| PCT×NEUT% | 182.5 | 0.861 | 0.770~0.951 | 0.000 | 88.7 | 72.7 | 84.0 | 72.7 | 88.7 |
| 炎性指标 | 最佳临界值值 | 曲线下面积 | 95%可信区间 | P值 | 敏感性/ % | 特异性/ % | 准确度/ % | 阴性预测值/% | 阳性预测值/% |
|---|---|---|---|---|---|---|---|---|---|
| PCT/（μg/L） | 2.295 | 0.852 | 0.758~0.946 | 0.000 | 87.9 | 72.1 | 83.6 | 71.5 | 88.1 |
| WBC计数/（×109/L） | 26.47 | 0.505 | 0.365~0.644 | 0.949 | 17.0 | 100.0 | 41.3 | 33.3 | 100.0 |
| NEUT#/（×109/L） | 19.435 | 0.545 | 0.404~0.686 | 0.541 | 24.5 | 95.5 | 45.3 | 34.4 | 92.9 |
| NEUT%/% | 85.55 | 0.713 | 0.583~0.842 | 0.004 | 67.9 | 68.2 | 68.0 | 46.9 | 83.7 |
| CRP/（mg/L） | 162.5 | 0.638 | 0.499~0.777 | 0.061 | 60.4 | 72.7 | 64.0 | 43.2 | 84.2 |
| PCT×NEUT% | 182.5 | 0.861 | 0.770~0.951 | 0.000 | 88.7 | 72.7 | 84.0 | 72.7 | 88.7 |
| [1] | 曹红,肖杰生. 败血症的临床特点及诊断思路[J]. 新医学,2005,36(5):255-257. |
| [2] | 尚红,王毓三,申子瑜. 全国临床检验操作规程[M]. 4版. 北京:人民卫生出版社,2015. |
| [3] | 贾忠兰,毕福玲,张彩明. 新生儿败血症病原菌分布及耐药性分析[J]. 中华医院感染学杂志,2017,27(1):197-200. |
| [4] | 王松炎,欧佳美,王德生. 新生儿败血症病原菌与降钙素原水平相关性应用研究[J]. 中外医学研究,2019,17(19):56-58. |
| [5] | 叶晓涛,习慧明,张旭,等. 降钙素原及血培养阳性时间对严重败血症早期预后的价值[J]. 中华医院感染学杂志,2013,23(16):4075-4077. |
| [6] | 陈迎晓,李庆兴,王邦松,等. 败血症病原菌临床分布及耐药性研究[J]. 中华医院感染学杂志,2008,18(12):1786-1789. |
| [7] | 张晓红,邓子德. 败血症的病因和发病机制[J]. 新医学,2005,36(5):254-255. |
| [8] | 王国俊. 革兰阴性菌败血症的临床表现[J]. 人民军医,1993,(2):22-23. |
| [9] | 王春娟,雷刚平,刘俊娜,等. PCT、CRP、IL-6联合检测对细菌性血流感染的早期诊断价值[J]. 国际检验医学杂志,2019,40(13):1600-1602. |
| [10] | 熊英. 血流感染患儿血清降钙素原与C反应蛋白水平变化情况及细菌分布[J]. 临床合理用药杂志,2018,11(30):124-125. |
| [11] | 胡世杰. 细菌感染诊断中应用血清降钙素原定量检测的临床意义探究[J]. 中外医学研究,2019,17(9):58-59. |
| [12] | 黄晨静,夏华峰,王寅. 血清降钙素原定量检测在细菌感染诊断中的临床意义[J]. 检验医学,2015,30(10):980-982. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
